Sugi Predict
/ Targets
/ UBE2L3
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to UBE2L3 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma |
PHASE2 | WITHDRAWN |
| Olaparib in Patients With HRD Malignant Mesothelioma |
PHASE2 | RECRUITING |
| Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma |
PHASE2 | SUSPENDED |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) |
PHASE1 | COMPLETED |
| Studying TAK-243 in Patients With Advanced Cancer |
PHASE1 | RECRUITING |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine |
PHASE1 | COMPLETED |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) |
nan | UNKNOWN |
| A Natural History Study of Angelman Syndrome |
nan | RECRUITING |
| Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma |
nan | COMPLETED |
| Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome |
nan | COMPLETED |
| Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors |
nan | NOT_YET_RECRUITING |
| Endocrine Disruptors and Life STILe in Breast Cancer Development |
nan | UNKNOWN |
| Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit |
nan | COMPLETED |
| A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS |
nan | RECRUITING |
| Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome |
nan | RECRUITING |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 |
nan | RECRUITING |
| Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas |
nan | RECRUITING |
| HRQoL and Financial Toxicity in Patients With VEXAS Syndrome |
nan | RECRUITING |
| The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin |
nan | UNKNOWN |
| Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 |
nan | RECRUITING |
| ADAPT: Efficacy of a Dietary Supplement During and After Exercise |
nan | COMPLETED |
| Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2 |
nan | UNKNOWN |
| Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease |
nan | UNKNOWN |
| DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy |
nan | ACTIVE_NOT_RECRUITING |
| Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders |
nan | RECRUITING |
| Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. |
nan | UNKNOWN |
| Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk |
nan | NOT_YET_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a UBE2L3 binder may also engage these)